April 2007 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

April 2007

Pharmaceutical Technology


Companies receiving the Feb. 26 Warning Letters are Actavis Totowa LLC; Anabolic Laboratories; Bio Pharm Inc.; Breckenridge Pharmaceutical Inc.; Centrix Pharmaceutical Inc.; DRX Pharmaceutical Consultants Inc.; DSC Laboratories; Excellium Pharmaceutical Inc.; Ferndale Laboratories, Inc.; IVAX Pharmaceuticals Inc. (formerly Goldline Laboratories Inc.); Kaiser Foundation Hospitals; Lini Inc.; Murfreesboro Pharmaceutical Nursing Supply; Nucare Pharmaceuticals, Inc.; Qualitest Pharmaceuticals, Inc; Sandoz, Inc.; The Harvard Drug Group LLC (formerly Major Pharmaceuticals Inc.); United Research Laboratories Inc. and Mutual Pharmaceutical Company; and Vintage Pharmaceuticals Inc.
-Maribel Rios

RESTRUCTURING

Bayer HealthCare Plans 6100 Job Cuts Worldwide

Berlin (Mar. 2)—Estimating it would save approximately EUR 700 million ($918 million), Bayer HealthCare ( http://www.bayerhealthcare.com/) will integrate the activities of its Pharma division with those of the former Schering AG, Germany. The company confirmed the action would eliminate nearly 6100 jobs worldwide, including 1000 in the United States and 3150 in Europe. Some 1850 production positions and 1400 global research and development functions will be cut by 2009.

Bayer Healthcare officials state the action is intended to "create slimmed-down and efficient structures and do away with double functions and overlaps."

"We said right from the start of the integration that job cuts would be necessary in order to achieve the synergy targets," said Werner Wenning, chairman of the Bayer AG Group Management Board and the Supervisory Board of Bayer Schering Pharma. "These essential streamlining measures are to be fairly implemented in a socially acceptable process, balanced across the globe. This includes the reduction of the number of locations, cutting down on structural and personnel overcapacity, the concentration of research and development activities, as well as the harmonization of structures and processes in marketing and administration."
-Maribel Rios


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here